Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

The dopamine transporter is decreased in the striatum of subjects with restless legs syndrome.

Earley CJ, Kuwabara H, Wong DF, Gamaldo C, Salas R, Brasic J, Ravert HT, Dannals RF, Allen RP.

Sleep. 2011 Mar 1;34(3):341-7.

2.

Increased synaptic dopamine in the putamen in restless legs syndrome.

Earley CJ, Kuwabara H, Wong DF, Gamaldo C, Salas RE, Brašić JR, Ravert HT, Dannals RF, Allen RP.

Sleep. 2013 Jan 1;36(1):51-7. doi: 10.5665/sleep.2300.

3.

Increased striatal dopamine transporter density in moderately severe old restless legs syndrome patients.

Kim KW, Jhoo JH, Lee SB, Lee SD, Kim TH, Kim SE, Kim YK, Yoon IY.

Eur J Neurol. 2012 Sep;19(9):1213-8. doi: 10.1111/j.1468-1331.2012.03705.x. Epub 2012 Mar 21.

PMID:
22435397
4.

Support for dopaminergic hypoactivity in restless legs syndrome: a PET study on D2-receptor binding.

Cervenka S, Pålhagen SE, Comley RA, Panagiotidis G, Cselényi Z, Matthews JC, Lai RY, Halldin C, Farde L.

Brain. 2006 Aug;129(Pt 8):2017-28. Epub 2006 Jul 1.

5.

Spinocerebellar ataxia type 1, 2, and 3 and restless legs syndrome: striatal dopamine D2 receptor status investigated by [11C]raclopride positron emission tomography.

Reimold M, Globas C, Gleichmann M, Schulze M, Gerloff C, Bares R, Machulla HJ, Bürk K.

Mov Disord. 2006 Oct;21(10):1667-73.

PMID:
16941469
6.

Presynaptic dopaminergic function in patients with restless legs syndrome: are there common features with early Parkinson's disease?

Linke R, Eisensehr I, Wetter TC, Gildehaus FJ, Pöpperl G, Trenkwalder C, Noachtar S, Tatsch K.

Mov Disord. 2004 Oct;19(10):1158-62.

PMID:
15390076
7.

Striatal dopaminergic function in restless legs syndrome: 18F-dopa and 11C-raclopride PET studies.

Turjanski N, Lees AJ, Brooks DJ.

Neurology. 1999 Mar 23;52(5):932-7.

PMID:
10102408
8.

SPECT imaging of striatal pre- and postsynaptic dopaminergic status in restless legs syndrome with periodic leg movements in sleep.

Michaud M, Soucy JP, Chabli A, Lavigne G, Montplaisir J.

J Neurol. 2002 Feb;249(2):164-70.

PMID:
11985381
9.

Altered dopaminergic profile in the putamen and substantia nigra in restless leg syndrome.

Connor JR, Wang XS, Allen RP, Beard JL, Wiesinger JA, Felt BT, Earley CJ.

Brain. 2009 Sep;132(Pt 9):2403-12. doi: 10.1093/brain/awp125. Epub 2009 May 25.

10.

Normal striatal D2 receptor binding in idiopathic restless legs syndrome with periodic leg movements in sleep.

Tribl GG, Asenbaum S, Happe S, Bonelli RM, Zeitlhofer J, Auff E.

Nucl Med Commun. 2004 Jan;25(1):55-60.

PMID:
15061265
11.

Sleep disorders in Machado-Joseph disease: a dopamine transporter imaging study.

Pedroso JL, Braga-Neto P, Felício AC, Minett T, Yamaguchi E, Prado LB, Carvalho LB, Dutra LA, Hoexter MQ, da Rocha AJ, Bressan RA, Prado GF, Barsottini OG.

J Neurol Sci. 2013 Jan 15;324(1-2):90-3. doi: 10.1016/j.jns.2012.10.008. Epub 2012 Nov 6.

PMID:
23137414
12.

PET imaging of dopamine transporter and drug craving during methadone maintenance treatment and after prolonged abstinence in heroin users.

Shi J, Zhao LY, Copersino ML, Fang YX, Chen Y, Tian J, Deng Y, Shuai Y, Jin J, Lu L.

Eur J Pharmacol. 2008 Jan 28;579(1-3):160-6. Epub 2007 Oct 10.

PMID:
17977528
13.

99mTc-TRODAT-1 SPECT as a Potential Neuroimaging Biomarker in Patients With Restless Legs Syndrome.

Lin CC, Fan YM, Lin GY, Yang FC, Cheng CA, Lu KC, Lin JC, Lee JT.

Clin Nucl Med. 2016 Jan;41(1):e14-7. doi: 10.1097/RLU.0000000000000916.

PMID:
26204215
14.

Lower dopamine transporter binding potential in striatum during depression.

Meyer JH, Krüger S, Wilson AA, Christensen BK, Goulding VS, Schaffer A, Minifie C, Houle S, Hussey D, Kennedy SH.

Neuroreport. 2001 Dec 21;12(18):4121-5.

PMID:
11742250
15.

Higher striatal dopamine transporter density in PTSD: an in vivo SPECT study with [(99m)Tc]TRODAT-1.

Hoexter MQ, Fadel G, Felício AC, Calzavara MB, Batista IR, Reis MA, Shih MC, Pitman RK, Andreoli SB, Mello MF, Mari JJ, Bressan RA.

Psychopharmacology (Berl). 2012 Nov;224(2):337-45. doi: 10.1007/s00213-012-2755-4. Epub 2012 Jun 15.

PMID:
22700036
16.

Striatal dopamine transporter availability in unmedicated bipolar disorder.

Anand A, Barkay G, Dzemidzic M, Albrecht D, Karne H, Zheng QH, Hutchins GD, Normandin MD, Yoder KK.

Bipolar Disord. 2011 Jun;13(4):406-13. doi: 10.1111/j.1399-5618.2011.00936.x.

PMID:
21843280
17.

Efficacy of cabergoline in restless legs syndrome: a placebo-controlled study with polysomnography (CATOR).

Oertel WH, Benes H, Bodenschatz R, Peglau I, Warmuth R, Happe S, Geisler P, Cassel W, Leroux M, Kohnen R, Stiasny-Kolster K.

Neurology. 2006 Sep 26;67(6):1040-6. Epub 2006 Aug 23.

PMID:
16931508
18.

Striatal and extrastriatal dopamine transporter in cannabis and tobacco addiction: a high-resolution PET study.

Leroy C, Karila L, Martinot JL, Lukasiewicz M, Duchesnay E, Comtat C, Dollé F, Benyamina A, Artiges E, Ribeiro MJ, Reynaud M, Trichard C.

Addict Biol. 2012 Nov;17(6):981-90. doi: 10.1111/j.1369-1600.2011.00356.x. Epub 2011 Aug 4.

PMID:
21812871
19.

In vivo quantification of dopamine transporters in mice with unilateral 6-OHDA lesions using [11C]methylphenidate and PET.

Fischer K, Sossi V, von Ameln-Mayerhofer A, Reischl G, Pichler BJ.

Neuroimage. 2012 Feb 1;59(3):2413-22. doi: 10.1016/j.neuroimage.2011.08.109. Epub 2011 Sep 14.

PMID:
21945469
20.
Items per page

Supplemental Content

Write to the Help Desk